pipette
ESEspañol

Change in gut microbiome precedes symptomatic Alzheimer's disease and is correlated with amyloid-beta accumulation in the brain

A. P. Shoubridge, S. K. Manning, S. Tan, S. Kidson, A. Richard, J. Trinder, S. Miller, K. Laver, M. Rahja, J. Robertson, M. Crotty, S. L. Taylor, G. B. Rogers

Preprint

In the authors' words

INTRODUCTION: Alzheimer's disease (AD) begins with cerebral amyloid-beta (A{beta}) deposition decades before clinical symptoms. While the microbiota-gut-brain axis has been implicated in AD, its role in this preclinical phase remains unclear. We examined potential links between gut microbiome features and presymptomatic cerebral A{beta} burden. METHODS: Asymptomatic individuals (n=101, median age 70.0 years, 53% female) underwent cognitive assessment, cerebral A{beta} quantification, and stool metagenomic sequencing. Associations between microbial characteristics and A{beta} levels were performed using multivariable-adjusted ordinal logistic regression. RESULTS: Gut microbiota composition varied with A{beta} levels (p(perm)=0.03, R2=0.014). Higher A{beta} was associated with increased Alistipes communis, and decreased Anaerotignum faecicola and Eubacterium rectale, abundance (q<0.001). A{beta}-associated microbiome traits corresponded to lower biosynthetic capacity for {gamma}-aminobutyric acid, and systemic regulators of immunity and autophagy (q<0.01). DISCUSSION: Early A{beta} accumulation is associated with distinct gut microbial signatures and reduced neuroactive metabolic potential, identifying targets for potential preclinical AD intervention.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, October 20. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.15.26365677